Nathan J Alves
Nathan J Alves
In an era where ultra-high antibody concentrations, high viscosities, low volumes, auto-injectors and long storage requirements are already complex problems with the current unconjugated monoclonal antibodies on the market, the formulation ...
T-cell receptor mimic (TCRm) antibody therapeutics against intracellular proteins [0.03%]
针对胞内蛋白的T细胞受体模拟(TCRm)抗体治疗药物
Yixiang Xu,Georgina To&#x;a Salazar,Ningyan Zhang et al.
Yixiang Xu et al.
T-cell receptor mimic (TCRm) antibodies combine the capacity of a T cell to target intracellular antigens with other capacities unique to antibodies. Neoantigens are abnormal proteins that arise as a consequence of somatic mutations. Techno...
Enhancing antibody-dependent cell-mediated cytotoxicity: a strategy for improving antibody-based immunotherapy [0.03%]
增强抗体依赖的细胞介导的细胞毒性作用：提高基于抗体的免疫治疗疗效的策略
David Zahavi,Dalal AlDeghaither,Allison O&#x;Connell et al.
David Zahavi et al.
The targeting of surface antigens expressed on tumor cells by monoclonal antibodies (mAbs) has revolutionized cancer therapeutics. One mechanism of action of antibody-based immunotherapy is the activation of immune effector cells to mediate...
Neutralizing antibodies against SARS-CoV-2: current understanding, challenge and perspective [0.03%]
关于新冠病毒的中和抗体：现状、挑战与未来视角
Yang Huang,Hui Sun,Hai Yu et al.
Yang Huang et al.
The rapid emergence of Coronavirus disease-2019 (COVID-19) caused by severe acute respiratory syndrome 2 coronavirus (SARS-CoV-2) as a pandemic that presents an urgent human health crisis. Many SARS-CoV-2 neutralizing antibodies (NAbs) were...
Mini-review: antibody therapeutics targeting G protein-coupled receptors and ion channels [0.03%]
简评：针对G蛋白偶联受体和离子通道的抗体治疗药物
Catherine J Hutchings
Catherine J Hutchings
Antibodies are now well established as therapeutics with many additional advantages over small molecules and peptides relative to their selectivity, bioavailability, half-life and effector function. Major classes of membrane-associated prot...
Emerging antibody-based therapeutics against SARS-CoV-2 during the global pandemic [0.03%]
全球大流行期间针对SARS-CoV-2的抗体新药研发进展
Yaping Sun,Mitchell Ho
Yaping Sun
SARS-CoV-2 antibody therapeutics are being evaluated in clinical and preclinical stages. As of 11 October 2020, 13 human monoclonal antibodies targeting the SARS-CoV-2 spike protein have entered clinical trials with three (REGN-COV2, LY3819...
Innate immune-mediated antiviral response to SARS-CoV-2 and convalescent sera a potential prophylactic and therapeutic agent to tackle COVID-19 [0.03%]
针对SARS-CoV-2的先天免疫抗病毒反应和恢复期血浆：对抗新型冠状病毒肺炎(COVID-19)的一种潜在预防和治疗手段
Abdullah,Shah Faisal,Komal Aman et al.
Abdullah et al.
The whole world is confronting the pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Unfortunately, there is no vaccine to prevent novel coronavirus infection. Besides several experimental drugs, the strong immune re...
Rapid exploration of the epitope coverage produced by an Ebola survivor to guide the discovery of therapeutic antibody cocktails [0.03%]
埃博拉病毒康复者广谱表位识别特性指导治疗性抗体药物研发
Tom Z Yuan,Ana G Lujan Hernandez,Erica Keane et al.
Tom Z Yuan et al.
Background: Development of successful neutralizing antibodies is dependent upon broad epitope coverage to increase the likelihood of achieving therapeutic function. Recent advances in synthetic biology have allowed us to ...
Convalescent plasma transfusion a promising therapy for coronavirus diseases 2019 (COVID-19): current updates [0.03%]
新型冠状病毒肺炎(COVID-19)康复期血浆治疗的最新研究进展及思考
Henu Kumar Verma,Batoul Farran,Lakkakula V K S Bhaskar
Henu Kumar Verma
While there is no proven treatment available for coronavirus disease 2019 (COVID-19), convalescent plasma (CP) may provide therapeutic relief as the number of cases escalate steeply world-wide. At the time of writing this review, vaccines, ...